Inhibition of De Novo NAD+ Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage  by Tummala, Krishna S. et al.
Cancer Cell
ArticleInhibition of De Novo NAD+ Synthesis
by Oncogenic URI Causes Liver
Tumorigenesis through DNA Damage
Krishna S. Tummala,1 Ana L. Gomes,1 Mahmut Yilmaz,1 Osvaldo Gran˜a,2 Latifa Bakiri,3 Isabel Ruppen,4
Pilar Xime´nez-Embu´n,4 Vinayata Sheshappanavar,5 Manuel Rodriguez-Justo,6 David G. Pisano,2 Erwin F. Wagner,3
and Nabil Djouder1,*
1Growth Factors, Nutrients and Cancer Group, BBVA Foundation-Cancer Cell Biology Programme, Spanish National Cancer Research
Centre, CNIO, 28029 Madrid, Spain
2Bioinformatics Unit, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre, CNIO, 28029 Madrid,
Spain
3Genes, Development, and Disease Group, BBVA Foundation-Cancer Cell Biology Programme, Spanish National Cancer Research Centre,
CNIO, 28029 Madrid, Spain
4Proteomics Core Unit, ProteoRed ISCIII, Biotechnology Programme, Spanish National Cancer Research Centre, CNIO, 28029Madrid, Spain
5Department of Pathology, Royal London Hospital, London E1 1BB, UK
6Department of Cellular Pathology, University College London NHS Trust, London NW1 2BU, UK
*Correspondence: ndjouder@cnio.es
http://dx.doi.org/10.1016/j.ccell.2014.10.002SUMMARYMolecular mechanisms responsible for hepatocellular carcinoma (HCC) remain largely unknown. Using
genetically engineered mouse models, we show that hepatocyte-specific expression of unconventional pre-
foldin RPB5 interactor (URI) leads to amultistep process of HCC development, whereas its genetic reduction
in hepatocytes protects against diethylnitrosamine (DEN)-induced HCC. URI inhibits aryl hydrocarbon (AhR)-
and estrogen receptor (ER)-mediated transcription of enzymes implicated in L-tryptophan/kynurenine/
nicotinamide adenine dinucleotide (NAD+) metabolism, thereby causing DNA damage at early stages of
tumorigenesis. Restoring NAD+ pools with nicotinamide riboside (NR) prevents DNA damage and tumor
formation. Consistently, URI expression in human HCC is associated with poor survival and correlates nega-
tively with L-tryptophan catabolism pathway. Our results suggest that boosting NAD+ can be prophylactic or
therapeutic in HCC.INTRODUCTION
Hepatocellular carcinoma (HCC) is the commonest, usually lethal,
humanprimary liver neoplasm (GLOBOCANv2.0, 2008). The early
stage is characterized by low- to high-grade dysplastic nodules,
‘‘preneoplastic lesions’’ (Kudo, 2009). These frequently develop
in chronic inflammatory liver disease or hepatitis, which can pro-
mote fibrosis, cirrhosis, and progression to HCC. Thus, precan-
cerous lesions have clinical value for HCC prediction (Libbrecht
et al., 2001), but therapeutic options are limited (El-Serag, 2011).Significance
HCC is the third leading cause of cancer death worldwide with
deficit-induced genotoxic stress is critical to initiate liver tumo
bolism and genome integrity. Because our findings are relevant
of NR, a vitamin B3 derivative, or other NAD+ boosters can b
induced NAD+ depletion-mediated DNA damage and carcino
Therapeutic intervention on metabolic alterations prior to ge
tumorigenesis.
826 Cancer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc.In early stages of many cancers, including HCC, oncogene
activation induces replicative stress, resulting in DNA damage
leading to chromosomal instability (CIN), which accelerates
tumor development (Teoh et al., 2008). DNA damage elicits a
key repair mechanism, the DNA damage response (DDR), initi-
ated by phosphorylation of checkpoint proteins Chk1, Chk2,
and p53 (Reinhardt and Schumacher, 2012). p53-dependent
responses, including cell cycle arrest and/or senescence, are
induced, limiting preneoplastic lesions’ growth.When DNA dam-
age is too pronounced, p53 engages an apoptotic program bylimited therapeutic options. Here we demonstrate that NAD+
rigenesis and unravel a critical link between nutrient meta-
in human HCC, we propose that nutritional supplementation
e used as preventive and curative therapies in oncogene-
genesis, especially in patients with precancerous lesions.
nomic instability should be further considered to prevent
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URI-Induced NAD+ Depletion Causes HCC Developmentupregulation of Bcl-2 family proteins (Noxa, Puma, Bid, and/or
Bax). p53 dysfunctions allow tumor cells to escape apoptosis,
and thus, mutations inactivating p53 are themost common alter-
ations observed in HCC (Reinhardt and Schumacher, 2012).
In pathophysiological situations, the balance between cell pro-
liferation and apoptosis can be altered, perturbing tissue homeo-
stasis. Apoptotic dysregulations are important in liver disease.
Insufficient apoptosis, eliminating mutated cells, combined
with inflammation-mediated proliferation can promote liver can-
cer development. Excessive or sustained apoptosis causes liver
injuries, increased hepatocyte regeneration, which enhances ge-
netic errors and predisposes to HCC (Malhi and Gores, 2008).
Still, the initiating hepatocarcinogenesis events remain unclear.
Developing experimental models mimicking distinct stages of
HCC development would help to explore molecular mechanisms
linking histopathological changes to hepatocarcinogenesis.
Unconventional prefoldin RBP5 interactor (URI), a member
of the R2TP/URI-prefoldin (PFD)-like complex containing the
heat shock protein 90 (HSP90) (Boulon et al., 2010), is an onco-
gene amplified in human ovarian carcinomas and downstream
effector of the growth factor and nutrient-regulated mTOR/
S6K1 signaling cascade (Theurillat et al., 2011). URI inhibits
phosphatase PP1g, thereby increasing S6K1 activity-dependent
survival signaling. Thus, URI/PP1g complexes maintain the
mitochondrial threshold for apoptosis in accordance to nutrient
availability. URI overexpression promotes survival, while its dele-
tion enhances cancer cell death (Djouder et al., 2007; Theurillat
et al., 2011). Prompted by these observations, and the fact
that HCC occurs on the basis of mitochondrial dysfunction-
mediated hepatocyte death and liver injury (Luedde et al.,
2014; Malhi and Gores, 2008), we investigate the role of URI in
hepatocarcinogenesis.
RESULTS
URI Expression in Mouse Hepatocytes Induces
Spontaneous Liver Tumors
We generated a Col1a1 knockin mouse (Figures S1A and S1B
available online), expressing human URI (hURI) via a tetracy-
cline-dependent transactivator controlled by the hepatocyte-
specific liver activated protein promoter (Figures S1C–S1E).
These mice, designated hURI-tetOFFhep, and littermates lacking
hURI expression are referred to hereafter as ‘‘mutants’’ and
‘‘controls,’’ respectively. Without doxycycline, hURI was ex-
pressed specifically in hepatocytes from one allele from E10.5
(Carpenter et al., 2005), roughly twice as much as mouse
URI (Figures 1A, S1F, and S1G), similar to the increase of URI
expression in human HCC (see below).
We observed no pathological signs in 3-week-old mutants. In
8-week-old mutants, hematoxylin and eosin (H&E) staining re-
vealed anisokaryotic clusters (Figure 1B) resembling low-grade
dysplastic nodules observed in human hepatitis (Libbrecht
et al., 2001). At 12 weeks the clusters developed into high-grade
dysplastic nodules (Figures 1B, S1H, and S1I), similar to human
large liver cell dysplasia (LLCD) (Libbrecht et al., 2001). Fibrosis
was detected at 8 weeks and increased over time until 24 weeks,
as assessed by Sirius Red (SR), Masson Trichrome, alpha
smooth muscle actin, type I collagen (COL1A1), and reticulin
staining (Figure S1J). Quantification showed that about 1% toCa3% of livers were SR positive in mutants, representing 100%
to 300% increase over littermates (Figure S1K). Increases in
fibrotic markers weremeasured by quantitative RT-PCR (Figures
S1L–S1N), but serum alanine aminotransferase (ALT) values
remained unchanged (Figure S1O).
Between 24–54 weeks macroscopic lesions including ade-
noma and early HCC emerged. Recent reports described malig-
nant transformation of human adenomas, but tumors in our
model developed simultaneously (Pilati et al., 2014). Between
54–65 weeks low-grade and differentiated HCC were fully
apparent, and between 65–75 weeks, 40% of mutants devel-
oped macroscopic high-grade tumors occupying 20%–60%
of the liver (Figures 1B, 1C, and S1P). There were 25%–50% of
hepatocytes that were Ki67-positive, suggesting aggressive
tumors (data not shown). According to World Health Organi-
zation criteria (WHO, 2008), all tumors were well/moderately
differentiated: 20% glandular/acinar, indicative of telangiectatic
variants, and 80% trabecular. No cholangiocarcinoma were
detected (Figure 1C). Serum glucose, ALT, and total bile
acids were affected (Figure S1Q). Surprisingly, serum albumin
was increased, suggesting that liver function might not be fully
compromised (Figure S1Q).
All mutants died at 85 weeks, with a median survival
of 76 weeks before complete liver failure (Figure 1D). Immuno-
histochemistry (IHC) and pathological analyses revealed hURI-
positive hepatocyte-like cells in 30% of mutant lungs with
HCC, indicating aggressive metastases (Figures S1R and S1S).
Histopathological characterization confirmed the presence of
heterogeneous tumors with collapsed reticulin fibers, suggesting
increased hepatocyte death and proliferation, as indicated by
Ki67 (Figure 1E). Increases in alpha fetoprotein (AFP) levels, a
clinical marker for human HCC varied, but all tumors displayed
dramatic increases in p53 abundance and phosphorylation (Fig-
ures 1E and 1F), suggesting that p53 may either carry mutations
or may be improperly folded (Trinidad et al., 2013), thus possibly
inactive.
Fully developed HCC appeared at 30 weeks in hepatocarcino-
gen diethylnitrosamine (DEN)-treated hURI-tetOFFhepmice (Ves-
selinovitch and Mihailovich, 1983) (Figure S1T). When hURI was
expressed from two alleles, increasing its expression to 6-fold
compared to heterozygous hURI-tetOFFhep mice, HCC were
detected at 10 weeks (Figure S1U), highlighting the importance
of URI dosage. Embryonic development was not involved
because liver tumors were also detected in mice kept on doxy-
cycline until 8 weeks (expressing hURI from 8 weeks) then trans-
ferred to normal (chow) diet (Figure S1V). Thus, hURI expression
in mouse hepatocytes induces spontaneous HCC.
Continuous URI Expression Is Essential for
Hepatocarcinogenesis
Ceasing hURI expression in 8-week-old mutants for 24 weeks
reduced fibrosis and abolished dysplastic foci and prevented
early tumors, without affecting liver-to-body weight ratios (Fig-
ures 2A–2D and S2A). S6K1 activity was increased in 24-week-
old mice, but remained constant when hURI expression ceased,
indicating that mTOR/S6K1 activation was hURI-independent
(Figure 2B). Switching hURI expression off until 60 weeks pre-
vented tumor development and normalized ALT levels (Figures
S2B–S2E). Similarly, when hURI was expressed for 24 weeks,ncer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc. 827
Figure 1. URI Expression in Mouse Hepatocytes Induces Spontaneous Liver Tumors
(A) Representative images of IHC stained liver sections from 3-week-old hURI-tetOFFhep mice using hURI and FLAG antibodies. Insets represent the periportal
area, showing hepatocyte specific hURI expression. (n > 10).
(B) Representative images of H&E stained liver sections from 3- (n > 6), 8- (n > 19), 12- (n > 11), and 32-week-old (n > 7) hURI-tetOFFhepmice. Bottom two rows are
representative images of whole livers from hURI-tetOFFhep mice at 32 and 75 weeks of age. Black dotted circles mark LLCD-like lesions and black arrows point
anisokaryotic clusters in mutant hURI-tetOFFhep mice. Yellow dotted circles depict adenoma and HCC at 32 and 75 weeks of age, respectively.
(C) Percentage of control and mutant hURI-tetOFFhep mice bearing liver abnormalities in 60- to 75-week-old-mice.
(D) Kaplan Meier curve of control (n = 17) and mutant (n = 17) hURI-tetOFFhep mice. Log rank test p = 0.0036; Hazard ratio = 0.1603.
(E) Representative images of H&E, IHC, and reticulin stained liver sections from control and four tumors derived from one mutant hURI-tetOFFhep. NT, PT, and
T denote nontumoral, peritumoral, and tumoral tissues, respectively.
(F) WB analysis of control and mutant hURI-tetOFFhep livers. ‘‘T’’ denotes tumor.
See also Figure S1.
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were apparent, then, switched-off for 28 weeks, only residual
anisokaryotic clusters were detected, but no adenomas or
HCCs (Figure 2E). However, ultrasound analysis demonstrated
that well/moderately differentiated HCC (above 60 weeks) did
not regress when hURI expression was ceased for 5 weeks (Fig-
ures S2F–S2H). Thus, continuous hURI expression is required for
the maintenance of preneoplastic lesions and early tumors.
Aggressive HCCs with sufficient genetic mutations become
URI independent, even though ceasing URI expression for a
longer time remains to be tested.828 Cancer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc.We genetically inactivated URI specifically in hepatocytes by
crossing URI(lox/lox) and serum albumin (SA)-CreERT2 mice
(Schuler et al., 2004). URI deletion in hepatocytes after tamoxifen
treatment to obtain URI(+/D)hep or URI(D/D)hepmice, was confirmed
by IHC and western blotting (WB) (Figures 2F and 2G). Homozy-
gous deletion of URI led to death of URI (D/D)hep mice around
10 days (Figure S2I). Disruption of tissue architecture, presence
of atypia, dilated veins with intrahepatic bleeding, signs of
necrosis, and inflammatory cell infiltration were observed by
H&E staining. Additionally, SR staining, collapsed reticulin
fibers, and increased ALT indicated that hepatocytes underwent
Figure 2. Continuous URI Expression Is Essential for Hepatocarcinogenesis
(A) Representative images of H&E stained liver sections from 32-week-old hURI-tetOFFhep mice fed with (+) or without () doxycycline (Dox) after dysplatic lesion
formation at 8 weeks. Dotted black circle represents premalignant lesions. (nR 5).
(B) WB analysis of hURI-tetOFFhep livers as described in (A).
(C) Representative images of Sirius Red stained liver sections from mice described in (A). (nR 5).
(D) Quantification of Sirius Red stained liver sections from mice described in (C). (nR 5).
(E) Representative images of full livers and H&E stained liver sections from hURI-tetOFFhep mice treated with Dox for 28 weeks. Treatment started at 24 weeks of
age, after the appearance of dysplastic lesions, adenomas, and early HCC. Dotted black circles denote reminiscent anisokaryotic areas. (nR 5).
(F) Representative images of IHC stained liver sections for endogenous URI in URI(+/+)hep, URI(+/D)hep, and URI(D/D)hep mice. (nR 3).
(G) WB liver analysis for endogenous URI in URI(+/+)hep, URI(+/D)hep, and URI(D/D)hep livers.
(H) Representative images of whole livers from URI(+/+)hep and URI(+/D)hep mice treated with diethylnitrosamine (DEN) and sacrificed at 24 weeks of age. Dotted
yellow circles depict liver tumors. (nR 5). Bottom pictures represent reticulin stained livers, black circle depicts the dysplastic area.
(I) Tumor burden of mice described in (H).
(J) Serum ALT levels from mice described in (H).
Data represented as mean ± SEM (p% 0.05 = *). See also Figure S2.
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that these mice die from fulminant liver failure (Figures S2J and
S2K). However, URI(+/D)hep mice, in which URI expression was
approximately halved (Figures 2F and 2G), supplied a liver dam-
age-inducing 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-
supplemented diet, presented significantly less liver damage
and fibrosis as shown by ALT, SR, and reticulin stainings (Figures
S2L–S2N). Thus URI reduction protects from hepatocyte injury.
DEN-treatment increased URI levels in 3-week-old URI(+/+)hep
mouse livers and in wild-type murine HCC (Figures S2O
and S2P). Moreover, DEN induced tumor development at
24 weeks in 60% of URI(+/+)hep mice and enhanced ALT levels,
but URI(+/D)hepmice did not show any tumors at this age and dis-
played normal ALT values (Figures 2H–2J). Levels of cytochrome
P4502E1and 1A1catalyzingDENwere unchanged in 3-week-oldCalivers ofDEN-treatedURI(+/+)hep andURI(+/D)hepmice (FigureS2O),
suggesting that halving URI levels does not affect DEN bio-
activation (Kang et al., 2007). Thus, while complete deletion of
URI induces liver injury, halving URI is beneficial to maintain liver
homeostasis and prevents liver injury and HCC development.
URI-Induced DNADamage Initiates Liver Tumorigenesis
To further elucidate the mechanisms of hepatocyte death and
their contribution to HCC, we checked for phosphorylation of
histone H2AX (gH2AX), a DNA damage marker that triggers
apoptosis via the p53-DDR pathway. gH2AX and p53 phosphor-
ylation and abundance did not differ in 1-week-old livers (Fig-
ure S3A). At 3 weeks, a nonpathological stage with no dysplastic
lesions, gH2AX, phosphorylation of the 32 kDa subunit of repli-
cation protein A (RPA32) at Ser-4 and Ser-8, and p53 abundancencer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc. 829
Figure 3. URI-Induced DNA Damage Initiates Liver Tumorigenesis
(A) Representative images of gH2AX IHC stained liver sections from 3-week-old hURI-tetOFFhep mice. Insets denote gH2AX positive nuclei. (n = 5).
(B) Quantification of (A).
(C) WB analysis of 3-week-old hURI-tetOFFhep livers.
(D) Representative images of gH2AX IHC stained liver sections from 8-week- and 12-week-old hURI-tetOFFhep mice. Dotted black shapes depict anisokaryotic
clusters positive for gH2AX. (n = 6).
(E) Quantification of (D).
(F) WB analysis of 8-week-old hURI-tetOFFhep livers
(G) WB analysis of 8-week-old hURI-tetOFFhep livers, with or without p53 inactivation.
(H) Reticulin and Sirius Red stained livers described in (G).
(I) Serum ALT levels of mutant mice with or without p53 inactivation. (n > 4).
(J) Kaplan-Meier survival curve of control and mutant hURI-tetOFFhep mice with and without p53 inactivation. (Log rank test p% 0.001.)
(K) Percentage of tumor incidence in hURI-tetOFFhep mice with or without p53 inactivation.
Data represented as mean ± SEM (*p% 0.05 and **p% 0.01). See also Figure S3.
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suggesting that DDR precedes precancerous lesions. While
p53-dependent apoptosis occurred in cells that unsuccessfully
repair DNA (cleaved caspase 3; Figure 3C), hepatocyte prolifer-
ation rate was reduced (Figures S3B and S3C), suggesting that
high proliferation is not the initial hepatocarcinogenic event.
gH2AX-positive nuclei were more abundant in older mutant
livers (8- to 12-week-old) with obvious dysplastic lesions.
Furthermore, Ser-345 phosphorylation (and hence activation)
of Chk1 was enhanced in mutants, but not Thr-68 phosphoryla-
tion of Chk2, suggesting single strand break (Reinhardt and
Schumacher, 2012) (Figures 3D–3F). Enhanced p53 phosphory-
lation at Ser-18 (Chk1 target), acetylation at Ac-lys379 (Ito et al.,
2001) (Figure 3F), and expression of p19ARF (Reinhardt and
Schumacher, 2012) (Figure S3D) indicate p53 stabilization.830 Cancer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc.Senescence-associated b-galactosidase activity, expression
of several p53 target genes, BAX, and p21 protein abundance
were increased in 8- and 12-week-old mutants, while expression
ofXiapwas decreased (Figures 3F, S3E, and S3F) (Reinhardt and
Schumacher, 2012), suggesting increased hepatocyte death as
also shown by collapsed reticulin fibers (Figure S3G). Increased
abundance of proliferating cell nuclear antigen, cyclin D1, and
Ki67-positive nuclei suggested compensatory proliferation (Fig-
ures 3F and S3H). Finally, MAD2, a CIN marker and downstream
effector of cyclin D1, was increased (Figure 3F). Thus, hURI
expression in hepatocytes induces genotoxic stress, apoptosis,
compensatory proliferation, and CIN.
To assess genotoxic stress-induced apoptosis in HCC devel-
opment, p53 was inactivated in hURI-tetOFFhep mice. In p53-in-
activated 8-week-old mutants (hURI (+/Ki); p53ERTAM (+/Ki)),
Cancer Cell
URI-Induced NAD+ Depletion Causes HCC Developmentcleaved caspase 3, Bax expression, and collapsed fibers were
decreased (Figures 3G and 3H). Furthermore, SR staining and
ALT levels were reduced (Figures 3H and 3I), indicating that
DNA damage-activated p53 is required for hepatocyte death
and liver injury. While apoptosis was drastically suppressed,
inactivation of p53 significantly reduced survival and accelerated
liver tumorigenesis (Figure 3J): 80% of mice displayed aggres-
sive HCC (Figure 3K). Deletion of Cdkn2a did not modify mouse
survival or tumor burden (data not shown). Thus, genotoxic
stress, rather than excessive apoptosis, is the critical initiating
event in liver carcinogenesis.
URI Causes DNA Damage and Liver Tumorigenesis by
Inhibiting De Novo NAD+ Synthesis
To identify URI-mediated hepatocarcinogenetic events, we first
examined mTOR activation, which had been implicated in HCC
development via DNAdamage (Menon et al., 2012). No increases
in S6K1 activity were detected at 1 week (Figure S4A). In sequen-
tial immunoprecipitation experiments, using 1-week-old liver ex-
tracts, free hURI molecules were revealed by WB after complete
depletion of PP1g (Figures S4B and S4C), and vice versa (data
not shown). When 3-week-old mice were supplied a rapamy-
cin-containing diet, progression to preneoplastic abnormalities
continued, if not further pronounced (data not shown). Thus,
although a fraction of hURI binds PP1g, hURI apparently has a
PP1g-independent role in DNA damage and liver tumorigenesis.
Additionally, no differences in reactive oxygen species (ROS)
were observed in 1- and 8-week-old livers (Figures S4D and
S4E), suggesting that DNA damage is ROS-independent.
Global transcriptomic and proteomic profiling were performed
in a very early nonpathological stage and early premalignant
state (1- and 8-week-old livers). Transcripts’ sequencing re-
vealed small fractions of genes differentially expressed upon
hURI expression: 303 out of 12,295 genes at 1 week, and 740
out of 11,133 (false discovery rate [FDR] < 0.05) at 8 weeks (Fig-
ures 4A and S4F). Similarly, isobaric tags for relative and abso-
lute quantification (iTRAQ) identified 2,394 proteins: 122 and
597 of which were differentially expressed in 1- and 8-week
livers, respectively (Figures 4B and S4G; Table S1).
Heatmapping revealed that most differentially expressed pro-
teins were downregulated (Figure S4H). Significant overlaps in
the differentially expressed transcripts and proteins at 1 and
8 weeks (Figures S4I and S4J), indicated hURI-dependent tran-
scriptional repression mechanisms. Ingenuity pathway analysis
(IPA) revealed that among canonical metabolic pathways, the
L-tryptophan/kynurenine catabolism leading to de novo nicotin-
amide adenine dinucleotide (NAD+) synthesis was one of the
most significant downregulated pathways (Figures 4C and S4K).
Enzymes implicated in the L-tryptophan/kynurenine degrada-
tion, including tryptophan 2,3-dioxygenase (TDO2) and arylfor-
mamidase (AFMID) catalyzing the initial rate-limiting step and
kynurenine 3-monooxygenase (KMO), kynureninase (KNYU), and
3-hydroxyanthranilate 3,4-dioxygenase (HAAO) were all downre-
gulated (Figure 4D). Gene set enrichment analysis (GSEA) (Subra-
manian et al., 2005), using the RNA sequencing data and Kyoto
Encyclopedia of Genes and Genomes database, corroborated
these defects (data not shown). WB confirmed that TDO2 and
AFMID expression was reduced >50% in these livers (Figures 4E
and S4L) and in adult livers expressing hURI (Figure S4M).CaNAD+ concentrations were reduced in 3- and 6-week mutant
livers (Figures 4F and S4N), while increases in TDO2, AFMID,
and NAD+ levels were detected in URI(+/D)hep livers (Figures 4G
and 4H). Consistent with previous observations (Konishi et al.,
1986), liver NAD+ levels were depleted in DEN-treated mice,
and URI reduction enhanced NAD+ levels (Figure S4O). Thus,
URI reduction enhances NAD+ de novo synthesis, potentially ex-
plaining the protective effect of URI deletion in HCC. Further-
more, NAD+ concentrations inversely correlated with URI levels
in four human HCC cell lines (Huh-7, HepG2, SNU-398, and
SNU-449). While URI depletion significantly increased NAD+
levels, URI overexpression reduced NAD+ values (Figure S4P).
URI overexpression in SNU-449 cells, which had high NAD+
values and low endogenous URI levels, increased their growth,
whereas URI depletion in Huh-7 and HepG2 cells displaying
high endogenous URI, significantly reduced their growth (Fig-
ure S4Q). URI-regulating NAD+ levels may therefore be relevant
for human liver tumorigenesis.
Depleting TDO2 and AFMID in HCC cell line SNU-449
significantly reduced NAD+ levels (Figure S4R). Importantly, 14C-
labeled NAD+ levels in four human HCC cell lines incubated with
14C-tryptophan reduced significantly following AFMID depletion
(Figure S4S), indicating that L-tryptophan degradation accounts
for de novo NAD+ synthesis. Furthermore, expression of key en-
zymes of three other pathways implicated in oncogenesis was
unaffected by hURI expression: SHMT1, G6PD, and GOT1 of
the glycine/serine/threonine, pentose phosphate and glutamine/
aspartate pathways, respectively (Figure S4T). Finally, expression
of nicotinamide phosphoribosyltransferase (NAMPT, implicated
in NAD+ biosynthesis through salvage reactions, Figure S4U)
and activity of poly (ADP-ribose) polymerase (PARP), the main
NAD+-consuming enzyme (Figure S4U) were not affected at early
stages (1week), and levels of NADHand several dehydrogenases
that reduce NAD+ to NADH were decreased (Figure S4U;
Table S2). Reduction of NAD+ is thus mainly due to downregula-
tion of L-tryptophan/kynurenine catabolism.
We next induced liver injury and hepatocyte proliferation in
C57BL/6 mice with DDC-supplemented diet for 4 days, treated
them with DMSO or Ro-61-8048, a KMO inhibitor, for the next
3 days, and sacrificed mice on day 8 (Figures S4V and S4W).
NAD+ concentrations were reduced and DNA damage foci
significantly elevated in Ro-61-8048-treated livers (Figures 4I–
4K). Thus, L-tryptophan/kynurenine pathway inhibition in vivo
leads to reduced NAD+ concentrations and DNA damage, reca-
pitulating effects of hURI expression. Finally, nontumorigenic
mouse liver cells AML-12, stably depleted of TDO2 and AFMID
and transplanted into immunodeficient mice, formed aggressive
tumors (Figure S4X), suggesting that inhibition of L-tryptophan
pathway leads to transformation and tumorigenesis.
We assessed whether DNA damage was a consequence
of inactivation of NAD+-consuming enzymes, such as SIRT1 or
PARP (Durkacz et al., 1980; Herranz et al., 2010). In SNU-449
cells, SIRT1 inhibition by EX-527, which may enhance NAD+,
reduced RPA32 phosphorylation, whereas activating SIRT1
with resveratrol, whichmay lower NAD+, increased phosphoryla-
tion of RPA32 (Figure S4Y). Because in our model NAD+ deficits
increased replicative stress, DNA damage is unlikely due
to SIRT1 inhibition alone. Additionally, in URI-overexpressing
SNU-449 cells, in which NAD+ levels were lowered (Figure S4P),ncer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc. 831
Figure 4. URI Causes DNA Damage and Liver Tumorigenesis by Inhibiting De Novo NAD+ Synthesis
(A) Volcano plots from RNA sequencing representing differentially expressed significant (blue) and unchanged (red) mRNA species in livers from 1- and 8-week-
old hURI-tetOFFhep mice. (n > 3).
(B) Histogram of differentially expressed proteins analyzed by iTRAQ in livers from 1- and 8-week-old hURI-tetOFFhep mice. Numbers of proteins significantly
downregulated (green) and upregulated (red) are shown. (n = 5).
(C) Top downregulated canonical metabolic pathways based on iTRAQ data from 8-week-old mice, analyzed by using IPA software.
(D) Scheme of de novo NAD+ synthesis. Fold change of protein expression detected in iTRAQ are represented within the brackets. Ro-61-8048 is an inhibitor
for KMO.
(E) WB analysis (left) and quantification of reduction (mutant over control, right) of TDO2 and AFMID of 8-week-old hURI-tetOFFhep livers.
(F) Liver NAD+ concentrations in 3-week-old hURI-tetOFFhep mice. (nR 10).
(G) WB analysis of URI(+/+)hep and URI(+/D)hep livers.
(H) NAD+ levels in livers from URI(+/+)hep and URI(+/D)hep mice. (n = 5).
(I) Liver NAD+ levels in C57BL/6 mice previously fed with DDC and treated with either DMSO (1%) or Ro-61-8048 (25 mg/Kg) compound. (nR 5).
(J) Representative images of gH2AX IHC stained liver sections from C57BL/6 mice described in (I). (n = 5).
(K) Quantification of (J).
Data represented as mean ± SEM (*p% 0.05 and ***p% 0.001). See also Figure S4 and Tables S1 and S2.
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Thus, modulating SIRT1 activity may affect PARP activity either
via modulation of NAD+ levels or through regulation of acet-
ylation-dependent PARP1 activity (Rajamohan et al., 2009).
Notably, URI overexpression increased RPA32 phosphorylation,
which was not further enhanced when PARP was inhibited (Fig-
ure S4Y). Finally, PARP activity was reduced in 3-week-old
mutants, while NAMPT expression remained unchanged (Fig-
ure S4Z). Thus, hURI-mediated NAD+ depletion may induce
DNA damage via PARP inhibition.
Restoring NAD+ Pools Protects from DNA Damage and
Prevents Tumor Formation
To investigate whether restoring NAD+ pools would prevent
dysplastic nodules and tumor formation, 3-week-old hURI-832 Cancer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc.tetOFFhep mice were supplied with a nicotinamide riboside
(NR) diet. NR significantly increased hepatic NAD+ concentra-
tions (Figure S5A) without affecting liver-to-body weight ratio
(Figure S5B). We detected dysplastic lesions and DNA damage
in all mutants on chow, but not in those on NR, which also had
reduced fibrosis, p53 abundance, and Ser-18 phosphorylation
(Figures 5A–5D, S5C, and S5D). Prolonged NR treatment pre-
vented tumor development and reduced ALT levels (Figures
5E–5G). Similarly liver tumors were prevented in 30-week-old
homozygous mutants with higher URI levels (Figure S5E).
Thus, restoring NAD+ pools protects from hURI-induced DNA
damage, preneoplastic lesions, and tumor development. Sur-
prisingly, 12-week-old homozygous mutants with full blown tu-
mors then on 48 weeks of NR regimen showed significant tumor
regression (Figures S5F and S5G), and their livers had high levels
Figure 5. Restoring NAD+ Pools Protects from DNA Damage and Prevents Tumor Formation
(A) Representative images of H&E and gH2AX IHC stained liver sections from 12-week-old hURI-tetOFFhep mice fed with either chow (nR 15) or NR diets started
at 3 weeks of age (nR 15). Dotted black lines indicate anisokaryotic clusters present in mutant hURI-tetOFFhep mice under chow diet.
(B) Quantification of dysplastic lesions in the hURI-tetOFFhep mice described in (A).
(C) Quantification of gH2AX positive nuclei in the hURI-tetOFFhep mice described in (A).
(D) WB analysis of mutant hURI-tetOFFhep livers as described in (A).
(E) Representative images of whole livers and H&E stained liver sections from 30- or 60-week-old hURI-tetOFFhep mice supplemented with NR diet from 3 weeks
of age until mice were sacrificed. (nR 10 for chow fed or NR fed.) Yellow dotted circles depict early tumors and black arrows point mitotic bodies.
(F) Tumor burden of 60-week-old mice described in (E).
(G) Serum ALT levels of 60-week-old mice described in (E).
(H) WB analysis of hURI-tetOFFhep mice expressing hURI for 8 weeks and switched OFF for 24 weeks.
(I) gH2AX IHC stained liver sections from 32-week-oldmutant hURI-tetOFFhepmice fedwith either chow or Dox diets. (n = 5). Red arrows point to DNAdamage foci.
Data represented as mean ± SEM (*p% 0.05 and ***p% 0.001). See also Figure S5.
Cancer Cell
URI-Induced NAD+ Depletion Causes HCC Developmentof cleaved caspase 3 (Figure S5H), suggesting that boosting
NAD+ levels may be cytotoxic for tumor cells.
Furthermore, ceasing hURI expression in 8-week-old mice for
24 weeks restored AFMID levels, suppressed DNA damage,
abolished the DDR, and reduced acetylation of p53 at Lys-379,
possibly due to activated NAD+-dependent SIRT1 (Luo et al.,
2001) (Figures 5H and 5I). Thus, continuous hURI expression
and consequent inhibition of de novo NAD+ synthesis is essential
for abolishing DNA repair and accelerating tumor formation.
Next, we explored whether other oncogenes had similar ef-
fects. Ela-1-myc mice, unlike K-RasG12V mice, develop pancre-
atic adenocarcinomas with high levels of DNA damage, while
pancreatic tumors initiated by K-RasG12V show no signs of repli-
cative stress (Murga et al., 2011). In early stages of tumori-
genesis, c-Myc, but not K-RASG12V, expression induced DNA
damage (Figures S5I and S5J). TOD2 and AFMID were clearly
downregulated in Ela-1-myc, but not in K-RasG12V pancreas (Fig-Caure S5K). In 3-week-old Ela-1-myc mice, 4 weeks of NR diet did
not affect acinar-to-ductal metaplasia (ADM), but 12 weeks of
NR diet decreased ADM and carcinomas formation compared
to chow fed mice (Figures S5L–S5O). Importantly pancreatic
NAD+ levels were significantly reduced in Ela-1-myc mutants
on chow diet, but restored to almost control levels on NR diet
(Figure S5P). Thus, oncogene-induced DNA damage has a
common bearing on NAD+ levels.
URI Regulates Kynurenine Metabolism by Modulating
AhR and ER Activity
We found significant overlaps in differentially expressed tran-
scripts between our RNA sequencing and published microarray
data sets for livers from aryl hydrocarbon receptor (AhR) and es-
trogen receptor (ER) knockout mice (Figures 6A, S6A, and S6B),
suggesting that AhR and ER mediate hURI-induced transcrip-
tional repression of L-tryptophan/kynurenine catabolism. TDO2ncer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc. 833
Figure 6. URI Regulates Kynurenine Metabolism by Modulating AhR and ER Activity
(A) GSEA using microarray data from Ahr/ and Esr/ livers and RNA sequencing data from 1 week hURI-tetOFFhep mice.
(B) WB analysis of human HepG2 cells transfected with scramble (siCtr) or siRNA against URI (siURI), AhR (siAhR), or ER (siER).
(C) Immunoprecipitation of cytosolic liver fractions from 1 week hURI-tetOFFhep mice and WB analysis.
(D) WB analysis of cytosolic fractions in livers from 1 week hURI-tetOFFhep mice.
(E) AhR and ER immunofluorescence of 1 week hURI-tetOFFhep liver sections. DAPI was used for nuclear staining. Lower panels depict nuclear colocalization
performed by using Image J. (n = 5).
(F) Quantification of nuclear colocalization of AhR and ER shown in (E).
Data represented as mean ± SD (**p% 0.01). See also Figure S6.
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in GSEA analysis. Depletion of AhR and ER in HepG2 cells
reduced expression of TDO2 (and AFMID), while URI downregu-
lation increased their abundance (Figure 6B). ALGGEN-PROMO
v3.0 software predicted several AhR and ER binding sites in
genomic sequences 5 kilobases upstream of the transcriptional
start sites of TDO2 and AFMID. Chromatin immunoprecipitation
assays revealed that both AhR and ER bound to these promoters
in SNU-449 cells (Figures S6C and S6D). We also verified hURI-
induced downregulation of other AhR and ER targets detected
in the RNA sequencing and iTRAQ analyses, including car-
bomyl-phosphate synthase 1, glutayl-CoA dehydrogenase,
and glycine N-methyltransferase 1 (GNMT1) (Figures S6E and
S6F). Notably, Gnmt1/ mice develop chronic hepatitis and
spontaneous HCC (Liao et al., 2009). Thus, hURI can repress
AhR and ER transcriptional activity, implicated in transcription
of several metabolic enzymes in particular from the L-tryptophan
catabolism pathway.834 Cancer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc.AhR and ER are in an inactive cytoplasmic complex with
HSP90, a member of the URI prefoldin complex (Boulon
et al., 2010; Knoblauch and Garabedian, 1999; Perdew, 1988).
Reciprocal coimmunoprecipitation experiments confirmed that
hURI and HSP90 interact with AhR or ER in cytosolic extracts
of 1-week-old mutant livers (Figure 6C). Cytoplasmic fractions
of mutant livers were also enriched with both nuclear receptors
(Figure 6D). Immunofluorescence analysis detected significant
reductions in nuclear AhR and ER in hepatocytes of 1-week-
old mutants (Figures 6E, 6F, and S6G). Finally, nuclear and
cytoplasmic fractionation of livers from 3-week-old DEN-
treated URI(+/+)hep mice showed a positive correlation between
URI expression and cytoplasmic AhR/ER localization, but
an inverse correlation between nuclear URI and AhR/ER. In
DEN-treated URI(+/D)hep livers, AhR and ER were enriched in
the nucleus (Figures S6H and S6I). Thus, hURI/HSP90 inhibitory
cytoplasmic complex prevents AhR and ER transcriptional
activity.
Figure 7. URI Expression Is Enhanced in HCC, Is Associated with Poor Survival, and Correlates with NAD+ Synthesis Inhibition
(A) Representative images of IHC stained for URI in human liver sections.
(B) Stratification of human samples according to URI expression as scored in (A). Values represent number of cases, and values within brackets represent
percentage of total.
(C) Kaplan Meier analysis of overall patient survival based on IHC for URI expression in HCC. URI positive includes weak, moderate, and strong signal in IHC
as described in (A). (Log rank test p = 0.0035; hazard ratio = 0.3163; and 95% confidence interval of ratio 0.1460 to 0.68).
(D) Stratification and correlation of URI expression in HCC samples with human HCC etiological factors.
(E) IHC for URI in normal and hepatitis human liver samples.
(F) Stratification of human hepatitis samples according to URI expression (n = 15). Values represent number of cases, and values within brackets represent
percentage of total.
(G) GSEA between differentially expressed genes in human HBV-associated HCC and RNA sequencing data sets from 1- and 8-week-old hURI-tetOFFhep mice.
(H) Linear regression analysis of URI1 and TDO2, KMO, and HAAO expressions in a human HCC microarray data set, showing inverse correlation between URI1
and TDO2, KMO, and HAAO expression.
(I) Multivariate Cox regression analysis for TDO2, KMO, HAAO, and QPRT, in a cohort of 221 HCC patients. (p = 0.025). ‘‘df’’ represents degrees of freedom
and ‘‘Sig.’’ represents significance. See also Figure S7.
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Associated with Poor Survival, and Correlates with De
Novo NAD+ Synthesis Inhibition
We examined URI in a tissue-microarray (TMA) of human liver
samples (82 HCC, 4 peritumoral, and 9 normal livers), using a
specific URI antibody (Figure S7A). No URI was detected in
normal livers, whereas various levels of URI were detected in
HCC (Figures 7A and 7B). Increased URI levels in 20 human
HCC, relative to paired peritumoral samples, were also detected
by real-time PCR (data not shown) and WB. URI was approxi-
mately 2-fold higher in 70% of the tumoral tissues as in the peri-
tumoral counterparts (Figures S7B and S7C), similar to hURI
expression in the hURI-tetOFFhep mouse. URI expression and
Ki67 stainingwere positively correlated (Figure S7D). Importantly,
URI expression was associated with poor prognosis (Figure 7C).CaData stratification indicated a significant correlation between
URI and hepatitis B virus (HBV)- or hepatitis C virus (HCV)-asso-
ciated HCC (Figure 7D). Increased URI expression was also
observed in human hepatitis samples, which predisposes to
hepatocarcinogenesis (Figures 7E and 7F). URI expression was
thus analyzed in a concanavalin A (ConA)-induced mouse hepa-
titis model. C57BL/6 mice administered with ConA had a
dramatic increase in hepatic URI after 4 to 8 hr. IHC analysis
confirmed that URI was confined to hepatocytes (Figures S7E
and S7F). Furthermore, HCC cell lines transiently transfected
with HBV viral protein HBx enhanced URI expression (Figures
S7G and S7H). When introduced into Huh-7 cells, expression
of a mouse Uri1 promoter luciferase reporter was increased
about 1.5-fold by HBx (Figures S7I and S7J). Finally, GSEA de-
tected significant overlaps between transcriptomic signaturesncer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc. 835
Figure 8. Scheme of URI-Induced HCC
Scheme representing molecular and cellular
events of hepatocarcinogenesis induced by URI
specifically expressed in hepatocytes. Hexagons
represent hepatocytes.
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associated human HCC (Figure 7G). Thus, in human HCC, URI
expression can be regulated by HBV infection or by infection-
induced inflammatory cues.
Next, we examined correlations between URI and L-trypto-
phan/kynurenine pathway. WB analysis of the paired peritu-
moral/HCC samples revealed that AFMID and NAD+ levels
were positively correlated, and both negatively correlated with
URI expression (Figures S7K–S7O). Analysis of a human HCC
gene expression data set (Wurmbach et al., 2007) showed in-
verse correlations between URI and TDO2, KMO andHAAO (Fig-
ure 7H). Finally, in a 221 patient data set (Roessler et al., 2010)
(Gene Expression Omnibus [GEO] ID: GSE14520), Cox regres-
sion analysis of TDO2, KMO, HAOO, and quinolinate phosphor-
ibosyltransferase (QPRT) expression, indicated that overall,
patients’ survival was significantly associated with L-tryptophan
catabolism signature (Figures 7I and S7P). Downregulation of
TDO2 or HAAO also correlated with poor prognosis for HCC
patients (Figures S7Q and S7R).
DISCUSSION
The presence of fibrosis/cirrhosis associated with chromosomal
abnormalities is the most convincing clinical aspect of HCC, but
the molecular mechanisms and pathogenesis of HCC are still
poorly understood (Teoh et al., 2008). Using GEMMs, URI-medi-
ated NAD+ depletion is shown to induce DNA damage, liver
injury, and multistep HCC (Figure 8).
Liver injury predisposes to HCC (Malhi andGores, 2008), but in
our model ALT values at precancerous stages are normal.
Normal ALT levels are observed in chronic HBV or HCV infected
patients withmild tomoderate histological liver damage (Nunnari
et al., 2013), indicating that ALT levels are not always determi-
nants for hepatic injuries. However, persistently elevated ALT
increase HCC risks and are clear indicators of HCC in patients
with viral hepatitis (Chen et al., 2011; Lee et al., 2010), suggesting
that chronic hepatocyte death is a key trigger of liver disease836 Cancer Cell 26, 826–839, December 8, 2014 ª2014 Elsevier Inc.progression (Luedde et al., 2014). Geno-
toxic stress-induced p53 is required for
apoptosis, but when p53 is inactivated
and hepatocyte death is reduced, carci-
nogenesis is accelerated. Thus, geno-
toxic stress via NAD+ deficits, rather
than high-grade apoptosis, initiates liver
tumorigenesis.
Therapies increasing NAD+ levels
(e.g., NR) can be used to prevent HCC
and cancers resulting from oncogene-
induced DNA damage, but it remains to
be determined whether boosting NAD+
is also therapeutic in nongenotoxiccancers. NR has also surprising therapeutic effects on fully
developed liver tumors. Given that DNA damage-mediated
chromosomal rearrangements are irreversible, boosting NAD+
levels may activate the mitochondria SIRT3, a proapoptotic
tumor suppressor (Verma et al., 2013) enhancing cancer cell
apoptosis and tumor regression. Elevated SIRT3 levels, specif-
ically in tumor cells responding to NAD+ boost, remain to be
elucidated.
Multiple epidemiologic studies report on the association be-
tween tryptophan-poor diets and increased specific cancer
types incidences (Surjana et al., 2010). Daily supplementation
of niacin, a NAD+ precursor, reduced esophageal cancer inci-
dence and mortality in a population with chronic nutritional defi-
ciency (Surjana et al., 2010), and, in which gut microbiota might
be altered. Gut bacteria cleave the side chain of tryptophan
(Burns and Demoss, 1962), limiting its concentration and use
in de novo NAD+ synthesis (Michael et al., 1964). The implication
of the intestinal microbiota was suggested in HCC development,
although NAD+ levels remain to be determined (Dapito et al.,
2012). Dysbiosis can also have a tumor promoting effect
(Schwabe and Jobin, 2013), and malnutrition altering the intes-
tinal flora induces HCC (Yoshimoto et al., 2013). Future
cartographic determination of patients’ microbiota and identifi-
cation of specific harmful bacteria in diseases would be impor-
tant to better understand the symbiosis between bacteria and
mammals.
Activating AhR or ER can also be beneficial in HCC. Inhibiting
AhR generates xenobiotic stress, which accelerates liver tumor-
igenesis (Walisser et al., 2005), and DEN-treated AhR/ mice
increased tumor incidence compared to their littermates, sug-
gesting that AhR may be tumor suppressive (Fan et al., 2010).
Several epidemiologic and animal studies also suggest a protec-
tive effect of estrogen (Naugler et al., 2007). Additionally, estro-
gen was effective in the treatment of traumatic liver injury (Hsieh
et al., 2007). The nongender disparity in HCC development in our
hURI mouse model is consistent with the role of ER inhibition in
HCC progression.
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stages of liver tumorigenesis, and combined therapies that syn-
ergistically activate AhR and ER should be tested in preclinical
models for HCC treatment, in particular in patients with high
URI expression. Finally, the development of more efficient and
stable NAD+ boosters could provide therapies to prevent or
cure cancers and associated metabolic dysfunctions.
EXPERIMENTAL PROCEDURES
Generation and Handling of Mice
All mice have been backcrossed to C57BL/6 for at least seven generations and
housed in pathogen-free conditions. All experiments were approved by the
Centro Nacional de Investigaciones Oncologicas (CNIO)-Instituto de Salud
Carlos III Ethics Committee and performed in accordance with the guidelines
for ethical conduct in the care and use of animals as stated in the international
guiding principles for biomedical research involving animals, developed by the
Council for International Organizations of Medical Sciences. Littermates were
always used as controls.
Liver Carcinogenesis, Injury Models, and Mouse Treatments
Fourteen-day-old mice were injected intraperitoneally with 25 mg/kg of DEN
(Sigma) (Vesselinovitch and Mihailovich, 1983).
For ConA treatment, 8-week-old C57/BL6 male mice were intravenously in-
jected with 15 mg/kg of ConA (Sigma Aldrich) and sacrificed at 2 hr intervals.
DDC was mixed with chow diet to a final concentration of 0.5% w/w (Harlan)
and supplied as indicated in the experiment.
Ro-61-8048 (Sigma-Aldrich, SML0233) was dissolved to 593 mM in DMSO.
The 9-week-old C57BL/6 mice were given DDC for 4 days and then switched
to chow and injected with either Ro-61-8048/Sunflower Seed Oil (25 mg/Kg) or
DMSO/Sunflower Seed Oil (1:100) intraperitoneally for three consecutive days.
Nicotinamide riboside (97% purity, Waterstonetech Pharma) was dissolved
in ice cold water and immediately mixed thoroughly with cold amorphous
chow diet (Harlan) at 500 mg/kg/day and supplied ad-libitum.
Tumor Quantification
Macroscopically visible tumor nodules were counted and sizes measured with
Vernier calipers. Total liver size was measured in the same position, and rela-
tive tumor burden was expressed as percentage of tumor volume relative to
the whole liver.
Human Samples
Human samples were obtained from the histopathology files of University Col-
lege Hospital, University College London (UCL), from patients after approval
by the Institutional Research Ethics Committee (Central London REC 3, Refer-
ence 06/Q0512/106) and from the CNIO-Biobank. The construction and anal-
ysis of a tissue microarray of HCC was approved by the appropriate ethics
committee, and informed consent was obtained from all subjects.
[14C]-Tryptophan Metabolic Tracing
HCC cells were transfected with siCtr or siAFMID grown in a 12 well plate
until they reached 60% confluence and starved for 5 hr for tryptophan
in tryptophan-free media. 2.5 mM of [benzene-ring-U-14C]-tryptophan was
provided to cells and incubated at 37C for 5 hr. Cells were then washed
three times with cold PBS, and metabolites extracted in a methanol and
water (80:20) mixture and incubated for 10 min at 4C. Metabolic lysates
were centrifuged at maximum speed for 20 min at 4C. Radiolabeled sam-
ples were separated by thin layer chromatography (TLC) using ammonium
acetate (1M, pH5) and ethanol (30:70) and cellulose F plates. Labeled
NAD+-[carbonyl-14C] was used as positive control to calibrate the relative
migration of labeled metabolites. TLC plates were dried and exposed to a
PhosphorImager.
Proteomic Analysis
Extracted liver proteins were digested using a modified filter aided sample
prep protocol. Peptides were labeled with iTRAQ reagents and samples
were pooled. The complex mixture was subjected to isoelectric focusing frac-Cationation. The resulting fractions were separated by on-line nano-liquid chro-
matography and analyzed by electrospray mass spectrometry (MS)/MS using
a linear trap quadrupole Orbitrap Velos mass spectrometer (Thermo Scienti-
fic). Raw files were searched against UniProtKB/Swiss-Prot mouse database
(release date, October 19, 2011; 16,407 entries) using MASCOT (Matrix Sci-
ence, 2013). Peptides were filtered at 1% FDR using a concatenated database
(see also Supplemental Experimental Procedures).
Reporter Assays
Evolutionarily conserved, 440 base pairs regulatory sequence of URI ORF
were cloned in pGL4.10-Luc vector to generate the URI reporter plasmid.
Huh-7 cells were transfected with 200 ng URI reporter and 5 ng Renilla encod-
ing plasmids using Lipofectamine 2000. After 2 days of transfection, cells
were analyzed using the Dual-Luciferase Reporter Assay System (#E1960,
Promega). Values after pCDNA3-GFP or pCDNA3-HA-HBx transfection were
normalized to a Renilla control.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism V5.0 software
(GraphPad Software, 2007). Statistical significance (p) (p % 0.05 = *, p %
0.01 = **, p% 0.001 = ***, and p% 0.0001 = ****) between the means of a min-
imum of three groups was determined using unpaired two-tailed Student’s
t test. Results are expressed as the mean value ± SD or ± SEM as indicated.
All results including WB analysis are representative of at least three indepen-
dent experiments. The Kaplan-Meier method was used to estimate survival
curves for mouse and human, and log rank was used to evaluate statistical dif-
ferences. Statistical parameter (FDR) estimates the probability of a gene set
with false positive finding. Normalized enrichment score allows comparison
of enrichment analysis results across gene sets. Cox regression and survival
analysis were performed for target genes in human HCC data sets, using
SPSS software (v20) (IBM, 2011).
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The proteomic data are deposited to the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the PRIDE partner reposi-
tory with the data set identifier PXD000296 (Vizcaino et al., 2013). RNA
sequencing data are available from GEO (http://www.ncbi.nlm.nih.gov/geo)
with the accession number GSE48654.
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